Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Elion

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Opinion in HIV and AIDS|November 25, 2015
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USARichard Elion, Megan Coleman
BMJ Open|March 9, 2013
Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) TrialElsayed Z Soliman, Mollie P Roediger, Daniel A Duprez, et al.
HIV Clinical Trials|June 13, 2008
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot studyRichard Elion, Edwin Dejesus, Michael Sension, et al.
AIDS (London, England)|July 1, 2010
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort StudyFrank J Palella, Stephen J Gange, Lorie Benning, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration ProjectSusanne Doblecki-Lewis, Albert Y Liu, Daniel J Feaster, et al.
HIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.
HIV Clinical Trials|January 9, 2007
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot studyRichard Elion, Calvin Cohen, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
AIDS Research and Human Retroviruses|July 1, 2009
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Opinion in HIV and AIDS|November 25, 2015
The preexposure prophylaxis revolution: from clinical trials to routine practice: implementation view from the USARichard Elion, Megan Coleman
BMJ Open|March 9, 2013
Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) TrialElsayed Z Soliman, Mollie P Roediger, Daniel A Duprez, et al.
HIV Clinical Trials|June 13, 2008
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot studyRichard Elion, Edwin Dejesus, Michael Sension, et al.
AIDS (London, England)|July 1, 2010
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort StudyFrank J Palella, Stephen J Gange, Lorie Benning, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 18, 2018
Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration ProjectSusanne Doblecki-Lewis, Albert Y Liu, Daniel J Feaster, et al.
HIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.
HIV Clinical Trials|January 9, 2007
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot studyRichard Elion, Calvin Cohen, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 studyPaul E Sax, Andrew Zolopa, Indira Brar, et al.
AIDS Research and Human Retroviruses|July 1, 2009
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263)Lisa Ross, Richard Elion, Randall Lanier, et al.
Pageof 3